Urologic cancer drugs

Companies developing drugs to treat bladder, kidney and prostate cancer.
−6.3%
over 1 month · S&P 500 −2.3%

Key indicators

Health
51 / 100
Fragile
Solid
Up over 1 year
8 of 12
Volatility
65%
Calm
Choppy
Profitability
−244%
Low
High
Health and price: against the other tags.